Patents Assigned to REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTD
-
Patent number: 11365260Abstract: An agonistic 4-1BB monoclonal antibody or an antigen binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising: a CDR1 region having an amino acid sequence as shown in SEQ ID NO: 1, a CDR2 region having an amino acid sequence as shown in SEQ ID NO: 2, and a CDR3 region having an amino acid sequence as shown in SEQ ID NO: 3, the light chain variable region comprising: a CDR1 region having an amino acid sequence as shown in SEQ ID NO: 4, a CDR2 region having an amino acid sequence as shown in SEQ ID NO: 5, and a CDR3 region having an amino acid sequence as shown in SEQ ID NO: 6. The monoclonal antibody is targeted towards h4-1BB, and specifically binds to h4-1BB to activate T cells for treatment of a variety of cancers.Type: GrantFiled: November 21, 2018Date of Patent: June 21, 2022Assignee: REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTDInventors: Wenjun Cui, Shuhua Guo
-
Patent number: 11155626Abstract: The present invention relates to the biomedicine field, in particular to an anti-human PD-L1 humanized monoclonal antibody and its applications. The invention obtains an anti-human PD-L1 humanized monoclonal antibody with good specificity, high affinity and stability by screening, and the antibody can specifically bind to human PD-L1 instead of binding to members of B7 family, and it can bind to active T-cells to strengthen the activation of T-cells, so it can significantly inhibit the growth of tumor.Type: GrantFiled: June 3, 2016Date of Patent: October 26, 2021Assignee: REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTDInventors: Yixiang Zhu, Shuhua Guo, Jiachun Zhang, Ge Li
-
Patent number: 11059890Abstract: The present invention relates to the biomedicine field, in particular to an anti-human PD-1 humanized monoclonal antibody and its applications. The invention obtains an anti-human PD-1 humanized monoclonal antibody with good specificity, high affinity and stability by screening, and the antibody can specifically bind to human PD-1 instead of binding to other members of CD28 family, block the binding of PD-L1 and PD-1 with CD80 and partially restore functions of T-cells, so it can significantly inhibit the growth of tumor.Type: GrantFiled: June 3, 2016Date of Patent: July 13, 2021Assignee: REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTDInventors: Ge Li, Shuhua Guo, Jiachun Zhang, Yixiang Zhu
-
Publication number: 20200325236Abstract: An agonistic 4-1BB monoclonal antibody or an antigen binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising: a CDR1 region having an amino acid sequence as shown in SEQ ID NO: 1, a CDR2 region having an amino acid sequence as shown in SEQ ID NO: 2, and a CDR3 region having an amino acid sequence as shown in SEQ ID NO: 3, the light chain variable region comprising: a CDR1 region having an amino acid sequence as shown in SEQ ID NO: 4, a CDR2 region having an amino acid sequence as shown in SEQ ID NO: 5, and a CDR3 region having an amino acid sequence as shown in SEQ ID NO: 6. The monoclonal antibody is targeted towards h4-1BB, and specifically binds to h4-1BB so as to activate T cells. The monoclonal antibody has application potential for treating a variety of cancers by means of an immunomodulatory effect.Type: ApplicationFiled: November 21, 2018Publication date: October 15, 2020Applicant: REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTDInventors: Wenjun CUI, Shuhua GUO
-
Patent number: 10772885Abstract: The disclosure generally relates to methods of treating an ocular disease, comprising administering an effective amount of a pharmaceutical composition to an eye of a subject in need thereof, wherein the pharmaceutical composition comprises nintedanib, or its salt, derivative, analog or polymorph, or combination thereof. The disclosure also relates to pharmaceutical composition or formulation, which can be used for treating ocular diseases. In another aspect, the disclosure provides method of making the pharmaceutical composition or formulation.Type: GrantFiled: May 19, 2017Date of Patent: September 15, 2020Assignee: REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTD.Inventors: Shuhua Guo, Jiewen Zhong, Xinting Yuan, Zongren Yao
-
Publication number: 20190224194Abstract: The disclosure generally relates to methods of treating an ocular disease, comprising administering an effective amount of a pharmaceutical composition to an eye of a subject in need thereof, wherein the pharmaceutical composition comprises nintedanib, or its salt, derivative, analog or polymorph, or combination thereof. The disclosure also relates to pharmaceutical composition or formulation, which can be used for treating ocular diseases. In another aspect, the disclosure provides method of making the pharmaceutical composition or formulation.Type: ApplicationFiled: May 19, 2017Publication date: July 25, 2019Applicant: REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTD.Inventors: Shuhua GUO, Jiewen ZHONG, Xinting YUAN, Zongren YAO
-
Publication number: 20190071501Abstract: The present invention relates to the biomedicine field, in particular to an anti-human PD-1 humanized monoclonal antibody and its applications. The invention obtains an anti-human PD-1 humanized monoclonal antibody with good specificity, high affinity and stability by screening, and the antibody can specifically bind to human PD-1 instead of binding to other members of CD28 family, block the binding of PD-L1 and PD-1 with CD80 and partially restore functions of T-cells, so it can significantly inhibit the growth of tumor.Type: ApplicationFiled: June 3, 2016Publication date: March 7, 2019Applicants: REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTD, REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTDInventors: Ge LI, Shuhua GUO, Jiachun ZHANG, Yixiang ZHU